Optimal Use of Ganciclovir and Valganciclovir in Transplanted Patients: How Does It Relate to the Outcome?
Objective. Organ transplant recipients receive immunosuppressive regimens to prevent transplant rejection, which put them at increased risk for opportunistic infections like cytomegalovirus (CMV). Ganciclovir and Valganciclovir are mostly used to prevent or treat CMV. Any incorrect use of the drug m...
Main Authors: | Maryam Mozaffar, Shahrzad Shahidi, Marjan Mansourian, Shirinsadat Badri |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | Journal of Transplantation |
Online Access: | http://dx.doi.org/10.1155/2018/8414385 |
Similar Items
-
Ganciclovir use evaluation in kidney transplantation departments
by: Maryam Mozaffar, et al.
Published: (2016-01-01) -
Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
by: Siavash Vaziri, et al.
Published: (2014-01-01) -
Valganciclovir—Ganciclovir Use and Systematic Therapeutic Drug Monitoring. An Invitation to Antiviral Stewardship
by: Alicia Galar, et al.
Published: (2021-01-01) -
Pediatric Dosing of Ganciclovir and Valganciclovir: How Model‐Based Simulations Can Prevent Underexposure and Potential Treatment Failure
by: Karin Jorga, et al.
Published: (2019-03-01) -
Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients
by: Buclin Thierry, et al.
Published: (2010-01-01)